| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Institute of Clinical Neuroscience, Department of Neurology, Göteborg University, Sahlgrenska University Hospital, Sweden.
Address correspondence and reprint requests to Dr. J. Lycke, Institute of Clinical Neuroscience, Department of Neurology, Göteborg University, Sahlgrenska University Hospital, SE-413 45 Göteborg, Sweden; e-mail: jan.lycke{at}neuro.gu.se
Objective: To determine if CNS-derived proteins present in the CSF of multiple sclerosis (MS) patients reflect different pathologic processes of MS and if these proteins could be useful as biologic markers of disease activity.
Methods: Concentrations of the neurofilament light protein (NFL), glial fibrillary acidic protein (GFAP), S100B, and the neuron-specific enolase protein (NSE) were determined in the CSF of 66 MS patients and 50 healthy control subjects with immunoassays.
Results: The mean levels of the NFL were increased during all stages of MS compared with controls (p < 0.001), peaking almost 10 times higher during acute relapses. The highest levels of GFAP were found during the secondary progressive course (p < 0.001) with a strong correlation with neurologic deficits (Expanded Disability Status Scale score, r = 0.73, p < 0.001). No increase of S100B or NSE protein was found in the CSF of MS patients compared with control subjects.
Conclusions: Increased level of NFL is a general feature of MS, indicating continuous axonal damage during the entire course of the disease with the most profound damage during acute relapses. GFAP may serve as a biomarker for disease progression, probably reflecting the increasing rate of astrogliosis.
Received March 31, 2003. Accepted in final form August 20, 2003.
This article has been cited by other articles:
|
|
 |
|
  N Mattsson, M Axelsson, S Haghighi, C Malmestrom, G Wu, R Anckarsater, S Sankaranarayanan, U Andreasson, S Fredrikson, A Gundersen, et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis Multiple Sclerosis, April 1, 2009; 15(4): 448 - 454. [Abstract] [PDF]
|
|
|
|
|
|
K. Rejdak, A. Petzold, Z. Stelmasiak, and G. Giovannoni Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis Multiple Sclerosis, January 1, 2008; 14(1): 59 - 66. [Abstract] [PDF]
|
|
|
|
 |
|
 A Mellgren, R. W. Price, L. Hagberg, L. Rosengren, B. J. Brew, and M. Gisslen Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection Neurology, October 9, 2007; 69(15): 1536 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Toda, N. Matsuki, M. Shibuya, I. Fujioka, S. Tamahara, and K. Ono Glial fibrillary acidic protein (GFAP) and anti-GFAP autoantibody in canine necrotising meningoencephalitis Vet Rec., August 25, 2007; 161(8): 261 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Petzold, M J Eikelenboom, G Keir, C H Polman, B M. Uitdehaag, E J Thompson, and G Giovannoni The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers Multiple Sclerosis, June 1, 2006; 12(3): 325 - 328. [Abstract] [PDF]
|
|
|
|
|
|
J Brettschneider, A Petzold, A Junker, and H Tumani Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis Multiple Sclerosis, April 1, 2006; 12(2): 143 - 148. [Abstract] [PDF]
|
|
|
|
 |
|
 A Petzold, M J Eikelenboom, G Keir, D Grant, R H C Lazeron, C H Polman, B M J Uitdehaag, E J Thompson, and G Giovannoni Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study J. Neurol. Neurosurg. Psychiatry, February 1, 2005; 76(2): 206 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. FRIEDBERG Astrocytic Activation as Evidence for Brain Damage Am J Psychiatry, January 1, 2005; 162(1): 195 - 196. [Full Text] [PDF]
|
|
|
|
|
|
R Ehling, A Lutterotti, J Wanschitz, M Khalil, C Gneiss, F Deisenhammer, M Reindl, and T Berger Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis Multiple Sclerosis, December 1, 2004; 10(6): 601 - 606. [Abstract] [PDF]
|
|
|
|
|
|
J. R. Avasarala, J. N. Lycke, C. Malmestrom, S. Haghighi, L. Rosengren, and O. Andersen Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS Neurology, August 10, 2004; 63(3): 599 - 599. [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
